Home > Resources > Whitepapers > Key Trends in Reshaping Future of Bio-pharmaceutical Harvest & Clarification

Key Trends in Reshaping Future of Bio-pharmaceutical Harvest & Clarification

August 31, 2019

Bioprocess performance (efficiency, robustness, and cost) is dictated by the overall strategy chosen to implement the processing platform. The permissible strategy space itself is enabled by the performance, availability and robustness of existing bioprocess technologies. Single use systems and membrane chromatography have considerably enlarged the range of strategies available in bioprocessing today.

Spotlight

Livongo

Livongo pioneered the category of Applied Health Signals™ to empower people with chronic conditions to live better and healthier lives. Livongo’s team of data scientists aggregate and interpret substantial amounts of health data and information to create actionable, personalized, and timely health signals. Livongo is the first company at the intersection of data science, behavior enablement, and clinical impact with the technologies and capabilities to silence Noisy Healthcare™. Our approach is leading to better clinical and financial outcomes while helping create a different and better experience for people with chronic conditions.

OTHER WHITEPAPERS

Further Discussion on Plasmids to Establish Release Specifications Using a Risk-Based Approach to Manage Supply

whitePaper | December 6, 2022

BioPhorum’s mission is to create environments where the global biopharmaceutical industry can collaborate and accelerate its rate of progress, for the benefit of all.

Bispecific Antibodies - CMC Considerations

whitePaper | December 16, 2022

Bispecific antibodies (bsAbs) are genetically engineered, recombinant antibodies that consist of two distinct binding domains.

HFPP Fraud, Waste, and Abuse in the Context of COVID-19

whitePaper | January 24, 2022

Since early 2020, coronavirus disease 2019 (COVID-19), caused by the severe acute respiratory syndrome.

Pioneering Cell and Gene Therapy Solutions From Discovery to the Clinic

whitePaper | April 14, 2020

Your vision is to create revolutionary cell and gene therapies to treat life threatening diseases. Bio-Techne and its family of brands is on this journey with you. As a full-solution ancillary reagent and services provider, we will stand by you, providing flexible and pioneering tools to simplify your workflow. From CAR T cells to pluripotent stem cells, let us help you get your therapy to the patients that need it

GMP Grade PMSF and Protease Inhibitors

whitePaper | February 23, 2023

Phenylmethylsulfonyl fluoride, better known as PMSF, is a small molecule serine protease inhibitor used to prevent unwanted proteolysis.

Accurate and reliable cell counting using holographic microscopy and machine learning algorithms

whitePaper | August 11, 2022

Reliable and accurate cell counts are crucial for many different purposes such as the maintenance of cell cultures in biological research or in-process controls in industrial bioprocessing.